Associated tags: Suicide, Depression, DSM-IV codes, NMDA, Post-traumatic stress disorder, Patient, Breakthrough, Ketamine, Therapy, FDA, PTSD, Food, Pharmaceutical industry, Dark Enlightenment, Breakthrough therapy, Lilly, Health, Letter, COVID-19, Novartis, Pfizer, US Foods, MPH, Fast Track, ASPE, National Security Advisor (United States), United States Army, JD, Biotechnology
Locations: DELAWARE, CALIFORNIA, UNION SQUARE, VIRGINIA, IV, PENNSYLVANIA
HOPE,
Therapy,
Patient,
New Drug Application,
FDA,
Ketamine,
Dark Enlightenment,
NDA,
ECT,
Suicide,
Electroconvulsive therapy,
Insurance,
DSM-IV codes,
Pharmaceutical industry This is designed with counsel to not be a taxable event for shareholders.
Key Points:
- This is designed with counsel to not be a taxable event for shareholders.
- "Incorporating HOPE Therapeutics is another important step in building value for NRx shareholders.
- HOPE is dedicated to providing an FDA-approved presentation of IV Ketamine, manufactured to current federal standards, in a diversion- and abuse-deterrent presentation.
- NRx also expects to convene a shareholder meeting in the coming weeks to vote on the planned structure of the spin-out of Hope Therapeutics and the stock dividend.
ECT,
Partnership,
Drug development,
Plasma protein binding,
FDA,
European,
Therapy,
REMS,
Keynote,
Dark Enlightenment,
MPH,
Mitigation,
Pharmaceutical industry "Ketamine's efficacy was so dramatic that ketamine became a standard of care ahead of the large clinical trials required for drug approval.
Key Points:
- "Ketamine's efficacy was so dramatic that ketamine became a standard of care ahead of the large clinical trials required for drug approval.
- Ketamine, as expected, now been demonstrated to be dramatically superior to placebo in large clinical trials.
- What could not be predicted is that ketamine has been shown to be at least as good as (i.e.
- We have partnered with Nephron Pharmaceuticals to develop a modern, single use, diversion- and tamper-resistant formulation of ketamine.
Retrieved on:
Wednesday, December 27, 2023
Nationally recognized attorney in highly regulated industries; healthcare specialist
Key Points:
- Nationally recognized attorney in highly regulated industries; healthcare specialist
RADNOR, Pa., Dec. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that Janet Rehnquist has been elected to the Company's Board of Directors where she will chair the compliance and the nominating committees.
- Ms. Rehnquist is an experienced healthcare lawyer who specializes in reimbursement and compliance matters.
- "I am excited to join the Board of NRx Pharmaceuticals - a biotech company focused on developing drug treatments to address urgent unmet medical needs in CNS and mental health, particularly suicidal depression.
- "We at NRx are thrilled to welcome someone with Janet's distinguished record and unquestioned integrity to the Board of NRx Pharmaceuticals" said Jonathan Javitt, MD MPH, Founder and Chief Scientist of NRx Pharmaceuticals.
Retrieved on:
Monday, December 18, 2023
CNS,
World Health Organization,
Composition,
Urinary tract infection,
Dark Enlightenment,
Urine,
QIDP,
IND,
GWU,
Baylor University,
DCS,
Nick Cuti,
Learning,
Hope,
NMDA,
Sepsis,
Patient,
FDA,
UTI,
Friends,
George Washington University,
Tropical medicine,
Bacteria,
University,
Composition of matter,
MD,
Accenture,
Engineering,
Death,
Failure,
Microbiology,
Hospital,
GSK plc,
Pharmaceutical industry,
Urology,
Immunology "Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.
Key Points:
- "Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.
- New treatment options are urgently needed" stated Jonathan Javitt, MD MPH, Founder and Chief Scientist of NRx Pharmaceuticals.
- "The D-cycloserine (DCS) component of NRX-101 is well known as an antibiotic and is excreted unmetabolized in the urine.
- The company awaits the FDA's response to its request for Qualified Infectious Disease Product (QIDP) designation, expected next month.
Retrieved on:
Monday, December 11, 2023
Therapy,
Dark Enlightenment,
Urine,
Pain,
GMP,
HOPE,
Beacon Grand Hotel,
Comment,
IND,
DCS,
Patient,
Alvogen,
FDA,
DSM-IV codes,
Cyclothymia,
Conference,
NIH,
Low back pain,
HEAL,
Powell Street,
Chronic pain,
Ketamine,
Bipolar,
Pharmaceutical industry RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.
Key Points:
- RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.
- NRx currently has four (4) near-term shots on goal with meaningful commercial and/or monetization opportunities:
NRX-100 – Intravenous Ketamine.
- NRx will be hosting 1x1 meetings at the Beacon Grand Hotel (450 Powell Street, a block away from the JP Morgan Conference at Union Square).
- To schedule a meeting, please register at LifeSci Partners Corporate Access Event 2024 and request a meeting with management.
Retrieved on:
Tuesday, November 7, 2023
RADNOR, Pa., Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the market closes on Tuesday, November 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
Key Points:
- RADNOR, Pa., Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the market closes on Tuesday, November 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
- The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30 p.m.
- A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events .
- Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-855-327-6837 or internationally +1 1-631-891-4304.
Partner,
FDA,
Good manufacturing practice,
Suicide,
Ketamine,
Dark Enlightenment,
US,
Research,
WEST,
CDC,
Caregiver,
Partnership,
United States Department of Veterans Affairs,
New Drug Application,
Depression,
Safety,
Nephron,
Defense,
Patient,
Edward Hines Jr. Veterans Administration Hospital,
Mental health,
Pharmaceutical industry Recent CDC data suggest that more than 3 million Americans have active thoughts of suicide and more than 50,000 die from suicide each year.
Key Points:
- Recent CDC data suggest that more than 3 million Americans have active thoughts of suicide and more than 50,000 die from suicide each year.
- "There are few efforts as important as playing a role - through research and development - in tackling the nation's mental health crisis," said Lou Kennedy CEO and owner of Nephron Pharmaceuticals.
- "To this end, we are honored to partner with NRx Pharmaceuticals in a groundbreaking endeavor.
- Together, we are advancing the production of single-dose, intravenous Ketamine, which could be a crucial breakthrough for the treatment of depression.
Retrieved on:
Thursday, September 14, 2023
Agreement,
Interim,
Bio-Rad Laboratories,
University,
Diagnosis,
Master of Science in Global Finance,
McKesson Corporation,
Pepperdine Graziadio Business School,
Pfizer,
LSA,
PwC,
Treasury,
Good,
Acquisition,
Financial audit,
Management,
Science,
Finance,
Lucira In connection with the Agreement, the Company appointed Richard Narido to serve as Interim Chief Financial Officer of the Company.
Key Points:
- In connection with the Agreement, the Company appointed Richard Narido to serve as Interim Chief Financial Officer of the Company.
- As Interim Chief Financial Officer, Mr. Narido will serve as the Company's principal financial officer and principal accounting officer.
- "I am pleased to welcome Richard to the team at NRx Pharmaceuticals.
- He brings great experience and energy to our dynamic company," said Stephen Willard, Chief Executive Officer of NRx Pharmaceuticals.
Retrieved on:
Thursday, September 7, 2023
RADNOR, Pa., Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference.
Key Points:
- RADNOR, Pa., Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference.
- The presentation is scheduled for Tuesday, September 12, 2023, at 5:00PM ET.
- The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue.
- Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.
Retrieved on:
Wednesday, August 30, 2023
Alvogen,
Priority review,
Patent,
Partnership,
Rockefeller Neuroscience Institute,
Nociception,
Schnitzer,
Spinal cord,
Drug discovery,
Clinical trial,
Licensure,
DSM-IV codes,
United States patent law,
Coronavirus Scientific Advisory Board,
Medication,
NMDA,
Research,
Brain,
Tylenol,
CNS,
Feinberg School of Medicine,
Dark Enlightenment,
Data collection,
Pain,
Thalamus,
Nonsteroidal anti-inflammatory drug,
Ketamine,
DCS,
FDA,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
IND,
Northwestern University,
Food,
Pharmaceutical industry,
Dietary supplement,
Vaccine,
Poultry farming,
Defense,
Anesthesia,
File,
Chronic pain,
Surgery The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.
Key Points:
- The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.
- Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
- Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.
- In experimental models and clinical studies, NMDA antagonists have demonstrated attenuation of pain and shown potential to reduce opioid craving.
